Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

PTC Therapeutics initiates reimbursed expanded access program for Translarna

PTC Therapeutics, Inc. today announced the initiation of a reimbursed expanded access program (EAP). PTC's EAP program is intended to make Translarna (ataluren) available to patients before commercial availability in certain countries.

9 Jul 2014

FDA grants Fast Track designation to Akashi Therapeutics' HT-100 for treatment of DMD

Akashi Therapeutics, Inc., announced today that the U.S. Food and Drug Administration has granted Fast Track designation to the company's most advanced product candidate, HT-100 (delayed-release halofuginone), an orally available, small molecule drug candidate intended to reduce fibrosis and inflammation and promote healthy muscle regeneration in boys with DMD.

3 Jul 2014

Children who undergo simple emergency surgeries on weekends are more likely to die

Children who undergo simple emergency surgeries, such as hernia repairs or appendix removals, on weekends are more likely to suffer complications and even die than children getting the same kind of treatment during the week, according to results of a Johns Hopkins Children's Center study.

1 Jul 2014

Vertex receives positive opinion from European CHMP for approval of KALYDECO for cystic fibrosis

Vertex Pharmaceuticals Incorporated today announced that the European Committee for Medicinal Products for Human Use has issued a positive opinion recommending the approval of KALYDECO (ivacaftor) for people with cystic fibrosis (CF) ages 6 and older who have one of eight non-G551D gating mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.

28 Jun 2014

Queen's doctor plays key role in major breakthrough to change lives of cystic fibrosis sufferers

A Queen's University doctor has played a key role in a major breakthrough to change the lives of cystic fibrosis sufferers.

26 Jun 2014

Sclerosis patients treated with HSCT experience better long-term event-free survival

Among patients with a severe, life-threatening type of sclerosis, treatment with hematopoietic stem cell transplantation (HSCT), compared to intravenous infusion of the chemotherapeutic drug cyclophosphamide, was associated with an increased treatment-related risk of death in the first year, but better long-term survival, according to a study in the June 25 issue of JAMA.

25 Jun 2014

Forest Laboratories reports positive results from three Phase III trials of vilazodone for GAD treatment

Forest Laboratories, Inc. today announced positive topline results from three Phase III trials evaluating the efficacy, safety and tolerability of vilazodone in adult patients with generalized anxiety disorder (GAD).

24 Jun 2014

Antiviral therapy can reduce risk of liver cancer in patients with chronic hepatitis B infection

One of the most severe complications of hepatitis B is the development of liver cancer, which is responsible for approximately 745,000 deaths worldwide each year.

24 Jun 2014

Aradigm begins Pulmaquin Phase III study for treatment of non-CF BE

Aradigm Corporation ("Aradigm" or the "Company") today announced the dosing of the first patient in the ORBIT-4 (Once-daily Respiratory Bronchiectasis Inhalation Treatment) Phase III pivotal clinical trial of Aradigm's proprietary formulation of inhaled ciprofloxacin (Pulmaquin®) for the treatment of non-cystic fibrosis bronchiectasis (non-CF BE).

23 Jun 2014

Emphysema does not worsen lung cancer prognosis beyond pulmonary fibrosis

Patients with combined pulmonary fibrosis and emphysema who are undergoing treatment for advanced lung cancer do not have a significantly worse prognosis than their counterparts with isolated idiopathic interstitial pneumonias, report Japanese researchers.

19 Jun 2014

Researchers demonstrate potential of retinoic acid in preventing type 2 diabetes complications

At a time when obesity, type 2 diabetes, and their complications are a veritable epidemic worldwide, researchers at the University of Montreal and CHUM Research Centre (CRCHUM) recently demonstrated the potential of retinoic acid (RA), a derivative of Vitamin A, in treating obesity and type 2 diabetes and preventing their cardiovascular complications.

17 Jun 2014

Using placental cells to repair damaged tissues: an interview with Zami Aberman, CEO, Pluristem Therapeutics

We start with birth and we collect the cells after C-section. The reason for that is we have to have the mother sign a consent letter that she is donating the placenta and, on top of that, we have to have a blood sample from the mother to test for any viral contamination.

16 Jun 2014

New imaging software measures growth of nodules in patients at risk of lung cancer

Medical-imaging software under development at Rochester Institute of Technology could someday give radiologists a tool for measuring the growth of nodules in patients at risk of lung cancer, the leading cause of cancer deaths in the United States, according to the Center for Disease Control and Prevention.

13 Jun 2014

Celsus’ expert highlights serious side effects of topical corticosteroids

A 2013 Mayo Clinic study involving more than 140,000 patients revealed that skin disorders are the most common nonacute reason Americans seek health care.

9 Jun 2014

Aradigm’s common shares approved for listing on NASDAQ Capital Market

Aradigm Corporation is pleased to announce that its common shares have been approved for listing on the NASDAQ Capital Market.

9 Jun 2014

Gene variants that lead to longer telomeres boost brain cancer risk

New genomic research led by UC San Francisco scientists reveals that two common gene variants that lead to longer telomeres, the caps on chromosome ends thought by many scientists to confer health by protecting cells from aging, also significantly increase the risk of developing the deadly brain cancers known as gliomas.

9 Jun 2014

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

Promedior, Inc., a clinical stage biotechnology company developing novel therapeutics for the treatment of fibrosis, today announced that Ruben Mesa, MD, will present interim data from the Company's ongoing Phase 2 clinical trial of its lead product candidate, PRM-151, for the treatment of myelofibrosis, in a poster presentation on June 14, 2014 at the 19th Congress of European Hematology Association (EHA) which is being held in Milan, Italy, from June 12-15, 2014.

5 Jun 2014

FCVB 2014 to feature cutting edge research in basic cardiovascular science

Cutting edge research in basic cardiovascular science will be presented at Frontiers in CardioVascular Biology (FCVB) 2014, held 4-6 July at the Palau de Congressos de Catalunya in Barcelona, Spain.

5 Jun 2014

Patient registry to help clinicians identify, manage people who have progressive lung disease

Duke Clinical Research Institute has launched a patient registry to help researchers and clinicians identify, manage and study people who have a progressive lung disease called idiopathic pulmonary fibrosis.

5 Jun 2014

New book documents groundbreaking studies on modified citrus pectin

One of the nation's leading writers on the use of naturopathic medicine has released a new book documenting groundbreaking studies on modified citrus pectin (MCP) and its application for addressing serious health issues like cancer, heart disease, chronic inflammation and fibrosis.

4 Jun 2014

Fibrosis News and Research

Further Reading

PTC Therapeutics initiates reimbursed expanded access program for Translarna

FDA grants Fast Track designation to Akashi Therapeutics' HT-100 for treatment of DMD

Children who undergo simple emergency surgeries on weekends are more likely to die

Vertex receives positive opinion from European CHMP for approval of KALYDECO for cystic fibrosis

Queen's doctor plays key role in major breakthrough to change lives of cystic fibrosis sufferers

Sclerosis patients treated with HSCT experience better long-term event-free survival

Forest Laboratories reports positive results from three Phase III trials of vilazodone for GAD treatment

Antiviral therapy can reduce risk of liver cancer in patients with chronic hepatitis B infection

Aradigm begins Pulmaquin Phase III study for treatment of non-CF BE

Emphysema does not worsen lung cancer prognosis beyond pulmonary fibrosis

Researchers demonstrate potential of retinoic acid in preventing type 2 diabetes complications

Using placental cells to repair damaged tissues: an interview with Zami Aberman, CEO, Pluristem Therapeutics

New imaging software measures growth of nodules in patients at risk of lung cancer

Celsus’ expert highlights serious side effects of topical corticosteroids

Aradigm’s common shares approved for listing on NASDAQ Capital Market

Gene variants that lead to longer telomeres boost brain cancer risk

Interim data from Promedior’s PRM-151 Phase 2 myelofibrosis clinical trial to be presented at 19th EHA Congress

FCVB 2014 to feature cutting edge research in basic cardiovascular science

Patient registry to help clinicians identify, manage people who have progressive lung disease

New book documents groundbreaking studies on modified citrus pectin

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News